Doubling new medicines spend: what the US pharmaceutical deal means for NHS priorities

The recent UK-US pharmaceutical deal commits to doubling spend on innovative medicines over the next decade. For an NHS balancing elective recovery, workforce pressures and neighbourhood health, this raises hard questions: where should the uplift land, what gets traded off to deliver it, and who decides? This session brings NHS, policy and industry voices together to debate the trade-offs and test whether the commitment can deliver value for patients, the system and the economy.